The rats were given either a placebo or CBD at 30 to 60 days after birth, with three experiments following. In the first experiment schizophrenia-like behaviors such as locomotor activity, social interaction and cognitive impairments were assessed on day 90. Side effects commonly associated with antipsychotic treatment were also evaluated throughout the treatment, including body weight gain and muscular rigidity and involuntary movement of the mouth, 48 hours post-treatment interruption and on post-natal day 90. In the second experiment, serum levels of triglycerides and glycemia were assessed on post-natal day 61. In the third experiment, levels of chronic pain, mood disorders and their metabolites were evaluated on post-natal days 61 and 90 in the prefrontal cortex and striatum.
The evaluation of these varied experiments determined that CBD administered to rats with an animal model of schizophrenia prevented the emergence of schizophrenia symptoms and lessened cognitive impairments. The treatment did not induce any motor or metabolic side effects. Treatment with CBD increased the prefrontal cortex 5-HIAA/serotonin ratio and the levels of 5-HIAA on post-natal days 61 and 90, respectively.
This study provides preclinical evidence for a safe and beneficial effect during treatment with CBD on preventing schizophrenia. More studies are required, however, to determine dosage and efficacy in adolescents to prevent the emergence of schizophrenia.
To read the full article, click here.